How many 8-K filings has Eyepoint, Inc. filed?

Eyepoint, Inc. (EYPT) has 29 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Eyepoint, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Eyepoint, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Eyepoint, Inc. (EYPT) — 8-K Filings

All 8-K filings from Eyepoint, Inc.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

8-K Filing — May 6, 2026
EyePoint Pharmaceuticals Files 8-K — Dec 8, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on December 8, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The c
EyePoint Pharmaceuticals Files 8-K — Nov 19, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on November 19, 2025, reporting other events and financial statements. The company, formerly known as pSivida Corp.
EyePoint Pharmaceuticals Files 8-K on Financials — Nov 5, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financ
EyePoint Pharmaceuticals Enters Material Definitive Agreement — Oct 17, 2025 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on October 14, 2025, the entry into a material definitive agreement. The company, formerly known as pSivida Corp. and p
EyePoint Pharmaceuticals Files 8-K — Oct 14, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting on results of operations, financial condition, and other events. The filing also incl
EyePoint Pharmaceuticals Files 8-K on Financials — Aug 6, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, and filing financial statements a
EyePoint Pharmaceuticals Announces Executive and Board Changes — Jun 20, 2025 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on June 18, 2025, several key executive and board changes. The company appointed Dr. Marc O. Classen as Chief Medical O
EyePoint Pharmaceuticals Files 8-K — May 27, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on May 27, 2025, reporting other events and financial statements. The company, formerly known as pSivida Corp. and p
EyePoint Pharmaceuticals Files 8-K — May 7, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations, other events, and financial statements. The company, formerl
EyePoint Pharmaceuticals Files 8-K — Mar 5, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on March 5, 2025, reporting on its results of operations and financial condition, and including financial statements
EyePoint Pharmaceuticals Files 8-K — Mar 4, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting on other events and financial statements. The company, formerly known as pSivida Corp. a
EyePoint Pharmaceuticals Files 8-K — Feb 5, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on February 5, 2025, reporting its status as a Delaware corporation with its principal executive offices in Watertow
EyePoint Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting its status as a public company. The filing confirms its principal executive offices a
EyePoint Pharma Shuffles Execs and Board — Jan 8, 2025 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on January 8, 2025, several key executive and board changes. The company appointed Dr. Marc O. Spiegel as Chief Medical
EyePoint Pharmaceuticals Files 8-K — Dec 4, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on December 4, 2024, to report other events and financial statements. The company, formerly known as pSivida Corp.,
EyePoint Pharmaceuticals Enters Material Definitive Agreement — Oct 31, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on October 28, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as pSivida Corp.
8-K Filing — Oct 28, 2024
EyePoint Pharmaceuticals to be Acquired for $1.4 Billion — Oct 24, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on October 22, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Intrepid Investm
EyePoint Pharma Appoints Dr. Guyer CEO, Miller Departs Board — Sep 4, 2024 Risk: medium
EyePoint Pharmaceuticals, Inc. announced on September 3, 2024, the appointment of Dr. David R. Guyer as Chief Executive Officer and a member of the Board of Dir
EyePoint Pharmaceuticals Files 8-K on Financials — Aug 7, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting on its Results of Operations and Financial Condition, and submitting Financial Statemen
EyePoint Pharmaceuticals Files 8-K — Jun 26, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. reported on June 26, 2024, that its common stock is trading on The Nasdaq Global Market under the symbol EYPT. The company is inc
EyePoint Pharmaceuticals Announces Board and CFO Changes — Jun 21, 2024 Risk: medium
On June 20, 2024, EyePoint Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, includin
8-K Filing — May 28, 2024
EyePoint Pharmaceuticals Files 8-K on Financials — May 8, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial s
8-K Filing — May 6, 2024
EyePoint Pharmaceuticals Files 8-K on Financials — Mar 7, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on March 7, 2024, reporting on its results of operations and financial condition. The filing also includes financial
EyePoint Pharmaceuticals Files 8-K — Mar 4, 2024 Risk: low
EyePoint Pharmaceuticals, Inc. filed an 8-K on March 4, 2024, reporting other events and financial statements. The company, formerly known as pSivida Corp. and
EyePoint Pharma Files Routine 8-K, Confirms Nasdaq Listing — Jan 10, 2024
EyePoint Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, indicating a routine update to its corporate information, specifically regarding its business a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX